CARL

8-K - CARLSMED, INC. (0001794546) (Filer)

10-Q - CARLSMED, INC. (0001794546) (Filer)

8-K - CARLSMED, INC. (0001794546) (Filer)

First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the first quarter ended March 31, 2026.  "We began 2026 with strong momentum, delivering 58% year-over-year revenue growth, publishing meaningful clinical data, and debuting new products to continue to advance our mission of improved patient outcomes and reduced cost of healthcare," said Mike Cordonnier,

CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will participate in the following investor conferences. Bank of America Global Healthcare Conference in Las Vegas, NV. Fireside chat on Tuesday, May 12, 2026, at 4:20 PM PT. A live webcast will be available to registered participants, and management will host one-on-one meetings on the same day.Jefferies Global Healthcare Conference in New York, NY. The Company will host one-on-one meetings on Thursday, June 4, 2026.Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Fireside cha

DEFA14A - CARLSMED, INC. (0001794546) (Filer)

DEF 14A - CARLSMED, INC. (0001794546) (Filer)

CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call. Event Date: Tuesday, May 5, 2026Time: 1:30 PM Pacific Time Participant Registration: https://register-conf.media-server.com/register/BI34a01ff77922411f8b9d41f912e4159b

CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET. A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/cCMfZsH5ZqrwSNTwfC9JDv/RczDxtnmshQKpi2ivHQcH3 About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and bey

4 - CARLSMED, INC. (0001794546) (Issuer)

S-8 - CARLSMED, INC. (0001794546) (Filer)

10-K - CARLSMED, INC. (0001794546) (Filer)

Fourth quarter revenue of $15.2 million; 61% growth YoY  Full year revenue of $50.5 million; 86% growth YoY  CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.  "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion to 76.5%, and reduction of our lead times to within six business days. These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture o

8-K - CARLSMED, INC. (0001794546) (Filer)

CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.   A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/d69xRqMspwymhwGUDdQoes/JC9qqvWhWggYawxGnDNtmz About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healt

CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced the first personalized cervical plating procedure using the corra™ Cervical Plating System, the latest addition to its portfolio of personalized spine surgery solutions. The procedure, which was performed by Dr. Aaron Clark at the University of California San Francisco (UCSF), represents an important milestone as the Company prepares for the planned commercial launch of the corra™ system later this year. "We're excited to expand our personalized cervical offerings following the recent launch of our aprevo® Cervical Interbody System," said Mike Cordonnier, Chairma

CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call. Event Date: Wednesday, February 25, 2026Time: 1:30 PM Pacific Time Participant Registration: https://register-conf.media-server.com/register/BIb45

CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced the successful completion of the first posterior lumbar spine surgery using the Company's aprevo® Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado. "This clinical milestone strengthens our position as a leader in personalized, data-driven spine solutions designed to help surgeons plan with greater precision, improve patient outcomes, and reduce costly revisions. The addition of the aprevo® Bi-lateral Posterior Lumbar Interbody Fusion procedure to o

4 - CARLSMED, INC. (0001794546) (Issuer)

4 - CARLSMED, INC. (0001794546) (Issuer)

4 - CARLSMED, INC. (0001794546) (Issuer)

4 - CARLSMED, INC. (0001794546) (Issuer)

8-K - CARLSMED, INC. (0001794546) (Filer)

Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced preliminary and unaudited revenue for the fourth quarter and year ended December 31, 2025. Preliminary Q4 & FY 2025 Revenue Results Fourth quarter 2025 revenue was approximately $15.2 million, an approximate 61% increase compared to the fourth quarter 2024.Full year 2025 revenue was approximately $50.5 million, an

CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication–related reoperations in complex adult spinal deformity (ASD) surgery. The study compared 2-year revision rates among ASD patients receiving Carlsmed's aprevo® personalized interbody implants with revision data from a similar patient cohort receiving conventional stock implants. The comparator cohort was drawn from the multicente